Tagraxofusp
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tagraxofusp: From CD4+/CD56+ Hematodermic Neoplasm to Esotropia
One-Sentence Summary
Tagraxofusp was originally used to treat CD4+/CD56+ hematodermic neoplasm (blastic plasmacytoid dendritic cell neoplasm, BPDCN). The TxGNN model predicts it may be effective for esotropia, but no clinical trials and no publications currently support this prediction. It rests on a graph-based score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | CD4+/CD56+ hematodermic neoplasm (the Singapore licence record contains no approved-indication text) |
| Predicted New Indication | Esotropia |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge of the drug, tagraxofusp is a CD123-directed cytotoxin (interleukin-3 fused to a truncated diphtheria toxin). It kills cells that express CD123, which is why it is effective in BPDCN, a CD123-positive neoplasm.
Esotropia is an eye-muscle misalignment disorder. No CD123-expressing pathogenic cell population is known in this condition, so no credible mechanistic link was identified between the original indication and the predicted one. The very high TxGNN score (0.997, rank 4210) reflects graph-based inference only and is not supported by any trial or literature.
Other top-ranked predictions are also weak or unsupported: pre-malignant neoplasm (a non-specific category, with only an indirect hematologic hypothesis), inner ear neoplasm, benign tongue neoplasm, chondroid hamartoma, childhood bronchial adenomas/carcinoids, ductal or ductular proliferation, non-seminomatous lesion, cystic neoplasm and thyroglossal duct cyst. Most of these are benign or surgically managed conditions, for which a systemic cytotoxic biologic is hard to justify.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN17059P | ELZONRIS Concentrate for Solution for Infusion 1000 mcg/mL | Infusion, solution concentrate | Not stated in the licence record |
The product is an injectable (intravenous infusion) with one valid single-ingredient licence and none cancelled.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted cytotoxic biologic (CD123-directed fusion protein with a diphtheria toxin payload) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert. Liver function and signs of capillary leak syndrome are expected to be key (see the hepatotoxicity and capillary leak concerns noted in the prediction rationale). |
| Handling Protection | Please refer to the package insert and local institutional rules for handling cytotoxic or hazardous drugs |
Safety Considerations
- Drug Interactions: 66 interactions were recorded, and the ones listed are all of Moderate level. Most involve glucose-lowering agents, including:
- Alpha-glucosidase inhibitors and DPP-4 inhibitors: acarbose, alogliptin, saxagliptin, linagliptin
- Biguanides, thiazolidinediones and sulfonylureas: metformin, pioglitazone, chlorpropamide, glimepiride
- SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin
- GLP-1 receptor agonists: albiglutide, dulaglutide, semaglutide
- Insulins: aspart, degludec, detemir, glargine, glulisine, human isophane
The list shown is only a subset of the 66 recorded interactions.
- Other concerns noted in the prediction rationale: capillary leak syndrome and hepatotoxicity are major systemic risks. They would be hard to justify in non-life-threatening or benign conditions.
For key warnings and contraindications, please refer to the package insert, as this data was not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or literature (evidence level L5), and no plausible mechanistic link exists between CD123-directed cell killing and esotropia. The drug's systemic toxicity also makes an unsupported repurposing for a benign eye condition unfavorable.
To proceed, the following is needed:
- Any biological evidence that CD123-expressing cells play a role in esotropia (currently none identified)
- Mechanism of action data from DrugBank
- HSA package insert warnings and contraindications, to allow safety screening
- Approved-indication text for the Singapore licence
- A risk-benefit justification for systemic use, given capillary leak syndrome and hepatotoxicity
- Consideration of the more mechanistically plausible hematologic hypotheses, such as CD123-positive clonal precursor conditions, instead of esotropia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.